Biologics in Pediatric Rheumatology: Quo Vadis?

Yonit Sterba, Norman Ilowite

Research output: Contribution to journalReview articlepeer-review

11 Scopus citations


The past two decades have brought immense satisfaction to pediatric rheumatologists and families of children with rheumatologic diseases. We have been able to better classify, recognize, and diagnose rheumatologic diseases, but most importantly, the discovery of biologic therapies and their efficacy and relative safety in treating multiple rheumatologic conditions, improving quality of life for the patients we care for. We will review the advances of the past two decades and discuss potential areas for new discoveries.

Original languageEnglish (US)
Article number45
JournalCurrent Rheumatology Reports
Issue number7
StatePublished - Jul 1 2016


  • Abatacept
  • IL-1 inhibitors
  • IL-6 inhibitors
  • Juvenile idiopathic arthritis (JIA)
  • Rituximab
  • TNF inhibitors
  • Tofacitinib

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Biologics in Pediatric Rheumatology: Quo Vadis?'. Together they form a unique fingerprint.

Cite this